FRE

Firebrick Pharma Limited

About FRE

Firebrick Pharma Limited (FRE) is a pharmaceutical company founded in 2012 to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company subsequently developed Nasodine® Nasal Spray (?Nasodine") and owns numerous granted and pending patents. Firebrick is currently undertaking two significant clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals.

Buy Australian shares starting with FRE. Invest today with a CHESS-sponsored broker!

Sector

Health Care

CEO

Industry

Pharmaceuticals

Website

firebrickpharma.com

Market Capitalisation

$20M

Price-earnings ratio

-5.83

Dividend yield

0.00%

High today

$0.20

Low today

$0.19

Open price

$0.20

52-week high

$0.50

52-week low

$0.19

Announcements

FRE FAQs

How much is one share of Firebrick Pharma Limited?

One share of Firebrick Pharma Limited is valued at $0.19.

What is the ticker symbol for Firebrick Pharma Limited?

The ticker symbol for Firebrick Pharma Limited is FRE.

How do I buy FRE shares in Australia?

To buy FRE stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake AUS
Deposit directly into your Stake wallet and you're ready to invest in FRE

What is the 52-week high for Firebrick Pharma Limited stock?

The Firebrick Pharma Limited 52-week high stock price is $0.50.

What is the 52-week low for Firebrick Pharma Limited stock?

The Firebrick Pharma Limited 52-week low stock price is $0.19.

What is the market capitalisation of Firebrick Pharma Limited FRE?

As of 18/03/2023 Firebrick Pharma Limited has a market cap of $20M.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.